With the field of HER2-positive breast cancer evolving rapidly, how will practice change in the clinic after the recent American Society of Clinical Oncology (ASCO) annual meeting?

In this final segment of MedPage Today 's expert roundtable, moderator Hope Rugo, MD, of the City of Hope Comprehensive Cancer Center in Duarte, California, asks panelists William Gradishar, MD, of Northwestern University Feinberg School of Medicine in Chicago, and Laura Huppert, MD, of the University of California San Francisco, what they'll take back to their patients. From possible first-line use of trastuzumab deruxtecan (T-DXd, Enhertu) to open questions around maintenance, the panel reflects on what's here now -- and what's still ahead.

Watch the entire roundtable series here .

Following is a transc

See Full Page